AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01360697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JADE
Description: 1. The nurse will complete the CA using standardized protocol including blood \& urine tests, eye \& feet examination.~2. Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~3. Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications \& healthy lifestyles, perform self blood glucose monitoring as appropriate.~4. At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight \& blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~5. After the FU visit, the patients will see the nurse or HCA again to clarify any issues \& concerns, reinforce compliance \& record any changes in medications.~6. After each FU visit, the HCA will generate summary reports to be given to patients \& doctors to promote sharing of information.
Study NCT01360697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-JADE
Description: Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
Study NCT01898455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RhinoChill intranasal cooling
Description: The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
Study NCT03726489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Daavlin 7 series 3 panel narrow band phototherapy home units
Description: Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors
Study NCT03726489 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: narrow band phototherapy clinic units
Description: Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
Study NCT02602769 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome profiling
Description: The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
Study NCT03917849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises program for patellar tendinopathy
Description: To compare the effectiveness of the inertial flywheel resistance program versus slow heavy resistance in patients with chronic patellar tendinopathy
Study NCT03046108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided injection
Description: Introduction of a needle based guided by ultrasound
Study NCT03046108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guided injection of mepivacaine
Description: ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
Study NCT03046108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guided injection of Triamcinolone
Description: ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
Study NCT01853020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.
Study NCT01853020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
Study NCT02592291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHealth
Description: The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
Study NCT02628639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Study NCT03274167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Study NCT03274167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study NCT00910104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven®
Description: 10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
Study NCT02969122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard gastrectomy with D2 lymphadenectomy
Description: standard distal or total gastrectomy and accorded D2 lymphadenectomy
Study NCT02969122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard gastrectomy with D2 lymphadenectomy
Description: standard distal or total gastrectomy and accorded D2 lymphadenectomy
Study NCT02969122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyperthermic intraperitoneal chemotherapy
Description: Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
Study NCT02969122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperthermic intraperitoneal chemotherapy
Description: Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
Study NCT02969122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extensive intraperitoneal lavage
Description: Lavage of peritoneal cavity with 1000ml saline for 10 times
Study NCT02969122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive intraperitoneal lavage
Description: Lavage of peritoneal cavity with 1000ml saline for 10 times
Study NCT02969122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative chemotherapy
Description: Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
Study NCT02969122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy
Description: SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
Study NCT02969122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Description: SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
Study NCT02542657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given PO
Study NCT02542657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02542657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02542657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT02777138 — intervention group
Intervention type: OTHER
Intervention: Maintaining a normal daily living lifestyle
Description: participants will undertake a normal lifestyle with no alterations to daily living in order to access the differences in tissue (muscle and adipose) and systemic inflammation between the two age cohorts
Study NCT02407808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC
Description: Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
Study NCT02407808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
Study NCT02407808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Study NCT02142140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic and Organization skills
Description: This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
Study NCT02142140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic and Organization skills
Description: This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
Study NCT02142140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Training
Description: The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
Study NCT02142140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
Study NCT02142140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training
Description: Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
Study NCT02142140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
Study NCT02142140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting stimulant
Description: The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
Study NCT02142140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting stimulant
Description: The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
Study NCT02140281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (cefadroxil alone)
Description: A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
Study NCT02140281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - AZD1722 followed by cefadroxil
Description: 15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
Study NCT02610166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game
Description: In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom.
Study NCT02610166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Children in usual care group receive standard medical care.
Study NCT03866291 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational
Description: See above
Study NCT04694209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary and mandibular telescopic retained overdentures supported by 4 implants
Description: The wax of the trial denture was converted into heat-cured acrylic resin using conventional packing and flasking techniques. The prosthesis was finished, polished and screwed in the patient's mouth. Engaging (Internal hex) cylindrical, plastic patterns (Octa plastic cylinder, multi unit abutment, Red, Dentis, Daegu -Korea) were used to construct the primary copings of the telescopic prosthesis.The finished primary copings were scanned using a lab scanner (Shera Echo-scan 7. Dental Wings, Montreal-Canada). This was necessary to design and to mill the wax pattern of the secondary copings using CAD/CAM technology (Dental Wings Software, Dental Wings, Montreal -Canada). Secondary coping was designed to properly fit to the primary coping. The framework was then tried in. At that time it was ready for its intra-oral luting to the secondary copings.
Study NCT04694209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary and mandibular screw retained hybrid prostheses supported by 4 implants
Description: Framework of the hybrid prosthesis is waxed using plastic copings attached to multiunit abutments. once the framework is finished , bite is recorded, teeth are set up and the waxed up prosthesis are tried in. IF accepted the wax is eliminated the wax up denture is converted inti heat cured acrylic resin
Study NCT02407808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Study NCT03122639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Study NCT03122639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Study NCT01474525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Glucose Telemonitoring System
Description: The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers.
Study NCT01474525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Blood Glucose Telemonitoring System
Description: The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers.
Study NCT03536013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other: Full-thickness placental allograft
Description: A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
Study NCT03647930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microporous Polysaccharide Hemospheres (MPH)
Description: Microporous Polysaccharide Hemospheres (MPH)
Study NCT02570984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: anti-ige injection
Study NCT02570984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator arm, injection similar to active
Study NCT00659802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004 low dose
Description: HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).
Study NCT00659802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching dose of Placebo
Study NCT00659802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004 high dose
Description: HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
Study NCT03608319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250
Description: 9.6 mg
Study NCT03519269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navio™ Robotics-assisted Surgical System
Description: Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
Study NCT04180397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide 10 mg/ml for injection/infusion
Study NCT04180397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline used as placebo (injection/infusion)
Study NCT03973229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol patch
Description: Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
Study NCT03973229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
Study NCT03973229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
Study NCT03973229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
Study NCT04375761 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of Biological Samples
Description: Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.